Status:
COMPLETED
Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia
Lead Sponsor:
HaEmek Medical Center, Israel
Conditions:
Thalassemia
Sickle Cell Disease
Eligibility:
All Genders
5-45 years
Brief Summary
Iron overload impaired growth in Thalassemia patients due to iron deposition in the endocrine glands, including the hypophysis and gonads. The issue of iron overload in Sickle Cell Anemia is recently ...
Detailed Description
Growth velocity, endocrine function and iron overload status will be studied in the patients that are in follow up at the Pediatric Hematology Unit, at the Ha'Emek Medical Center. Patients who were l...
Eligibility Criteria
Inclusion
- All patients in follow up with available medical charts.
Exclusion
- Patients lost from follow up or without enough data to calculate growth velocity or clinical and laboratory endocrine assessment or missing data about iron status.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
93 Patients enrolled
Trial Details
Trial ID
NCT00972231
Start Date
January 1 2009
End Date
December 1 2010
Last Update
September 1 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pediatric Hematology Unit - Ha'Emek Medical Center
Afula, Afula, Israel, 18101